HCW Biologics Past Earnings Performance
Past criteria checks 0/6
HCW Biologics's earnings have been declining at an average annual rate of -33.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 0.3% per year.
Key information
-33.1%
Earnings growth rate
44.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -0.3% |
| Return on equity | -185.7% |
| Net Margin | -879.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How HCW Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -25 | 13 | 8 |
| 30 Sep 23 | 3 | -20 | 13 | 8 |
| 30 Jun 23 | 4 | -19 | 11 | 9 |
| 31 Mar 23 | 4 | -18 | 10 | 10 |
| 31 Dec 22 | 7 | -15 | 8 | 9 |
| 30 Sep 22 | 5 | -13 | 7 | 8 |
| 30 Jun 22 | 4 | -12 | 7 | 8 |
| 31 Mar 22 | 3 | -12 | 6 | 8 |
| 31 Dec 21 | 0 | -13 | 5 | 8 |
| 30 Sep 21 | 4 | -8 | 4 | 8 |
| 30 Jun 21 | 4 | -8 | 4 | 7 |
| 31 Mar 21 | 4 | -8 | 3 | 8 |
| 31 Dec 20 | 4 | -7 | 3 | 7 |
Quality Earnings: HCWB is currently unprofitable.
Growing Profit Margin: HCWB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HCWB is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.
Accelerating Growth: Unable to compare HCWB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HCWB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: HCWB has a negative Return on Equity (-185.67%), as it is currently unprofitable.